Baxter International 2025 Q3 Earnings Significant Net Loss of $0.09 per Share -133.3%

Baxter International (BAX) reported its fiscal 2025 Q3 earnings on Nov 4, 2025, with mixed results. While earnings per share (EPS) exceeded estimates, revenue fell short, and the stock price declined sharply post-announcement. Investors must weigh these outcomes against ongoing legal challenges.

Revenue

, driven by strong performance across its diversified segments. Medical Products & , while Infusion Therapies & Technologies contributed $1.02 billion. , respectively. Healthcare Systems & Technologies and Care & Connectivity Solutions generated $773 million and $473 million, reflecting steady demand for digital health solutions. , underscoring the company’s broad portfolio. Despite these gains, , highlighting execution challenges.

Earnings/Net Income

Baxter International swung to a net loss of $0.09 per share in Q3 2025, a 133.3% negative change from $0.27 per share in Q3 2024. The company reported a net loss of $46 million, a 131.9% deterioration from a $144 million profit in the prior-year period. This sharp decline underscores operational pressures and legal liabilities.

Post-Earnings Price Action Review

The stock price of Baxter International declined 1.32% on the latest trading day, , and 24.81% month-to-date. This volatility reflects investor concerns over the company’s financial performance and legal risks. The absence of historical revenue beat data precludes a 30-day backtest strategy. Legal uncertainties, including securities fraud lawsuits over the Novum LVP’s safety, further complicate future outlooks. Investors are advised to prioritize risk management and monitor regulatory developments.

CEO Commentary

[No data available for CEO remarks from the earnings call transcript.]

Guidance

[No forward-looking guidance provided in the available data.]

Additional News

Baxter International faces multiple securities fraud lawsuits alleging misrepresentation of the Novum LVP pump’s safety. These lawsuits claim systemic defects caused patient harm and concealed risks of product pauses. Shareholders who purchased BAX stock between February 23, 2022, and July 30, 2025, may qualify to join class actions. The lead plaintiff deadline is December 15, . Legal actions involve firms like Rosen Law, Levi & Korsinsky, and Bernstein Liebhard, emphasizing the stock’s heightened regulatory and litigation risks.